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Abstract
Sox9 is an SRY-related transcription factor required for expression of cartilaginous genes in the developing skeletal system
and heart valve structures. In contrast to positively regulating cartilaginous matrix, Sox9 also negatively regulates matrix
mineralization associated with bone formation. While the transcriptional activation of Sox9 target genes during
chondrogenesis has been characterized, the mechanisms by which Sox9 represses osteogenic processes are not so clear.
Using ChIP-on-chip and luciferase assays we show that Sox9 binds and represses transactivation of the osteogenic
glycoprotein Spp1. In addition, Sox9 knockdown in post natal mouse heart valve explants and rib chondrocyte cultures
promotes Spp1 expression and matrix mineralization, while attenuating expression of cartilage genes Type II Collagen and
Cartilage Link Protein. Further, we show that Spp1 is required for matrix mineralization induced by Sox9 knockdown. These
studies provide insights into the molecular mechanisms by which Sox9 prevents pathologic matrix mineralization in tissues
that must remain cartilaginous.
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Introduction
The vertebrate skeletal system is primarily composed of
cartilage and bone, formed during embryonic development. Most
bones develop from replacement of cartilage through a process
known as endochondral ossification [1,2]. Cartilage formation is
initiated with condensation of undifferentiated mesenchyme
progenitor cells followed by proliferation and differentiation into
immature chondrocytes. As development progresses, chondrocytes
begin to secrete extracellular matrix (ECM) typical of cartilage
including type II collagen (Col2a1), before passing through a
transition stage to become hypertrophic [3]. In addition to
increasing in volume, hypertrophic chondrocytes secrete ECM
that is later mineralized. These cells then die, leaving behind a
calcified matrix that is eventually broken down, allowing invasion
of blood vessels and infiltration of bone-resorbing (osteoclasts) and
bone-forming (osteoblasts) cells. Many key regulators have been
shown to be required for cartilage and bone forming processes,
including the transcription factor Sox9.
Sox9 is an SRY-related hydroxymethylglutaryl (HMG) box
member of the Sox family and has been shown to regulate many
developmental events [4]. In the developing cartilage, Sox9 is
expressed in immature chondrocytes and its function is required
for mesenchyme cell condensation, proliferation and differentia-
tion [1,4]. This positive role of Sox9 during early stages of
chondrogenesis is largely attributed to its ability to bind and
transactivate SRY consensus sites within cartilage ECM genes;
these include Col2a1, Col9a2, Col11a2, Col27a1 and the proteogly-
cans Aggrecan and Cartilage Link Protein (CLP) [5,6,7,8,9,10]. In vivo,
mice with reduced Sox9 function fail to develop cartilage
[11,12,13] and mimic the human skeletal disorder, Campomelic
Dysplasia [13,14,15], further supporting a positive role for Sox9 in
promoting formation of cartilaginous connective tissue.
Following chondrocyte maturation, Sox9 expression is down-
regulated and levels remain low during stages of terminal
differentiation and matrix mineralization [4]. Enforced expression
in mature chondrocytes results in delayed endochondral ossifica-
tion [16], suggesting that Sox9 has a repressive role in bone
formation. Consistently, Sox9 haploinsufficiency leads to prema-
ture mineralization in many skeletal tissues [13]. Despite these
observations, the mechanisms of Sox9 function in bone are not
fully understood. In contrast to Sox9, expression of the transcrip-
tion factor Runx2 (cfba1) is high in mature chondrocytes and
osteoblasts [4,17,18,19]. It has previously been shown that Sox9
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including the glycoprotein, Spp1 [20], thereby repressing bone
formation. An additional mechanism of Sox9-mediated repression of
osteogenic processes includes findings by Hattori et al., [16] showing
that Sox9negativelyregulates Vegfato inhibit cartilage vascularization
and subsequent mineralization. Together these previous studies have
revealed pivotal roles for Sox9 in regulating formation of cartilage
and bone connective tissues in the skeletal system.
In addition to the skeletal system, we, and others have shown
that Sox9 is also expressed in the developing heart [21,22]. More
specifically, Sox9 is highly expressed in a population of
mesenchyme cells within the endocardial cushions that later give
rise to mature valve structures [23,24]. During early stages of
endocardial cushion formation, Sox9 is required to expand the
pool of proliferating mesenchyme precursor cells [21]. Following
endocardial cushion formation, Sox9 expression is maintained in
valve primorida and studies in mice suggest that similar to
functions in the skeletal system, Sox9 promotes cartilaginous
matrix phenotypes [23]. Remodeling heart valves from embryonic
Col2a1cre;Sox9
fl/fl mice express significantly reduced levels of
Col2a1 and CLP [21], while valves from viable Col2a1cre;Sox9
fl/+adult
mice are calcified and express high levels of osteogenic genes
including Runx2 and Spp1 [21,25]. This valvular phenotype in Sox9
mutant mice is consistent with human calcific valve disease,
frequently described as a pathological ‘bone-like’ process [26].
However, the molecular mechanism by which Sox9 prevents
pathological matrix mineralization in normal cartilaginous heart
valve connective tissue has not been examined.
In this study, we use a genome-wide microarray technique to
screen for interactions with novel target gene DNA enriched by
Sox9 chromatin immunoprecipitation (ChIP) in primary neonate
limb tissue. ChIP-on-chip analysis revealed Sox9 binding to over
450 promoters, including a region approximately 5000 bp
upstream of the osteogenic glycoprotein, Spp1. At the functional
level, luciferase assays show that Sox9 significantly represses Spp1
transactivation through interaction with an SRY binding site. Loss
of Sox9 function in primary heart valve explants and chondrocyte
cultures increases Spp1 transcript levels, while expression of
chondrogenic matrix genes including Col2a1 and CLP are
decreased. Conversely, Sox9 gain of function promotes Col2a1
and CLP expression. Finally, we show that Spp1 function is
required for matrix mineralization induced by Sox9 knockdown in
these culture systems. Taken together, these data suggest that in
maturing heart valves and chondrocytes, Sox9 negatively regulates
matrix mineralization through repressive regulation of Spp1.
Results
Identification of Sox9 binding to Spp1 by ChIP-on-chip
analysis
Our previous work has shown that several molecular pheno-
types and signaling pathways are common to the skeletal system
and heart valves. Similarly, Sox9 positively promotes cartilage and
negatively regulates matrix mineralization in both these systems
[13,21,23,25]. While the mechanisms of Sox9 during chondro-
genic processes have been well described, its molecular function in
mineralized connective tissues is less well understood. To address
this we performed ChIP-on-chip analysis using pooled Sox9
antibodies to enrich DNA/Sox9 complexes in chromatin isolated
from post natal mouse limb tissue, a time point when
endochondral ossification is active. Compared to IgG controls,
over 450 promoter regions showed enrichment of Sox9 binding at
levels comparable, or greater than the known target gene, CLP [8]
(Table S1). From this array of findings we focused our study on the
observed enrichment of Sox9 binding approximately 5000 bp
upstream of the transcriptional start site of Spp1 (Osteopontin), a
known regulator of osteoblast differentiation and mineralized
matrix deposition in vitro [27,28].
Using Genomatix MatInspector software, we identified three
canonical SRY binding sites within the 5000 bp candidate
enhancer region of Spp1, denoted SRY#1( 25065 bp), SRY#2
(24224 bp) and SRY#3( 21599 bp) (Figure 1A). In order to
determine which SRY site(s) Sox9 binds to, and validate ChIP-on-
chip observations, we performed three independent ChIP
experiments and tested for enrichment following Sox9 IP within
regions containing the putative SRY sites using specific primers. In
these additional ChIP experiments, expected enrichment of Sox9
binding over IgG controls was observed at a known functional
SRY binding site within the CLP promoter [8] (Figure 1B). In
addition, enriched Sox9 binding was also observed within the Spp1
enhancer region containing SRY#1( 25065 bp) (Figure 1). In
contrast, significant enrichment was not observed within regions
containing SRY#2( 24224 bp) or SRY#3( 21599 bp). These
studies suggest that Sox9 molecularly interacts with an SRY
binding site within the 5’ enhancer of Spp1.
Sox9 represses Spp1 promoter activity
To determine if the observed binding of Sox9 to the Spp1
enhancer region is functionally important, luciferase assays were
performed in HEK293 cells that express low levels of Sox9 and
Spp1, and MC-3T3 cells; a pre-osteoblastic cell line previously used
to examine transcriptional regulation of Spp1 [29]. In this
experiment, HEK293 and MC-3T3 cells were co-transfected with
either empty pcDNA or pcDNA-Sox9 in the presence of pGL3-
spp1; consisting of the 1599 bp 5’ Spp1 enhancer region containing
SRY#1 in front of the published 826 bp Spp1 promoter region
[30]. The normalized luciferase activity in cells co-transfected with
Figure 1. ChIP-on-chip analysis of Sox9 binding Spp1. (A)
Schematic to show representation of canonical SRY binding sites as
identified by Genomatix software within the 5’ region of Spp1. * indicate
nucleotides conserved across species. (B) qPCR analysis to show fold
enrichment of DNA/Sox9 complexes on SRY binding sites within the
Cartilage Link Protein (CLP) and Spp1 promoters. Fold changes in
enrichment are shown for three independent samples following
pulldown with pooled Sox9 antibodies, over IgG negative controls.
*Student’s t2test,0.05 compared to IgG.
doi:10.1371/journal.pone.0026769.g001
Transcriptional Regulation of Spp1 by Sox9
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considered ‘baseline’ of pGL3-spp1 activity in the two cell lines
(Figure 2A, 2B, top black bar). In contrast to pcDNA, co-
transfection with pcDNA-Sox9 consistently repressed pGL3-spp1
activity by 63%68% in HEK293 cells, and 60.3%612.6% in
MC-3T3 cells (Figure 2A, 2B, top grey bar). To examine the
specificity of Sox9 mediating this repression through SRY#1, site
directed mutagenesis was used to replace the Sox9/SRY core
binding sequence (A/T A/T CAA A/T) site from TACAAAG to
TAGCAGG (pGL3-spp1mut) [31]. The repressive effect of pcDNA-
Sox9 on pGL3-spp1 activity was not observed using the pGL3-
spp1mut construct, suggesting that Sox9-mediated repression of
Spp1 is through SRY#1. Worthy of mention, pcDNA-Sox9 had
no effect on activity of pGL3-empty or the spp1 enhancer region
(pGL3-spp1En) alone. However, pGL3-spp1p activity was signifi-
cantly increased in MC-3T3 but not HEK293 cells, independent
of SRY binding sites and exogenous Sox9 expression levels
(pcDNA vs. pcDNA-Sox9). As this Spp1 promoter region has
previously been shown to be regulated by a functional Runx2
binding site, luciferase assays were repeated in MC-3T3 cells using
a pGL3-spp1p mutant construct in which the Runx2 binding site
had been mutated from ACCACA to AGGAGA (pGL3-spp1pmut)
[30]. Activation of the spp1 promoter was significantly diminished
following mutation of Runx2 binding sites. This Runx2-mediated
activation of the spp1 promoter region is consistent with high levels
of endogenous Runx2 in MC-3T3, but not HEK293 cells
(Figure 2C). In summary, findings from these luciferase assays
show that Sox9 moderately represses Spp1 promoter activity.
Expression patterns of Sox9 and Osteopontin are
mutually exclusive in post natal heart valves and limbs
Previous studies by our group and others have shown that Sox9
and Spp1 play important roles in developing heart valves and
limbs [12,21,25,27]. Further, findings in this study suggest that
Sox9 molecularly interacts with (Figure 1) and negatively regulates
(Figure 2) Spp1. To support these observations, the temporal and
spatial expression patterns of Sox9 and Spp1 were examined in
heart valves and limbs using qPCR and immunohistochemistry
(Figure 3). In both tissues, Sox9 and Spp1 are most highly expressed
at E12.5 with a gradual decline to lower levels of expression by
post natal and adult (3 month) stages (Figure 3A, 3C). As expected
for a negative regulator, Sox9 expression is consistently higher than
Spp1 at all time points (Figure 3A, 3C). Spatially, immunohisto-
chemistry reveals that in both post natal hearts and limbs, Sox9
and Osteopontin (the protein product of Spp1) expression does not
overlap, consistent with the notion that Sox9 functions to repress
Osteopontin expression. In the heart, Sox9 is highly detectable
within valvular structures (tricuspid valve shown), while Osteo-
pontin expression is restricted to the subendocardial region and
myocardial ECM (Figure 3B): a region in which Sox9 expression
was not detected. In the limbs, Sox9 expression is consistent with
developing chondrocytes [11] (Figure 3B), while Osteopontin
expression is excluded from this expression domain [32]. These
expression studies suggest that spatially, expression of Sox9 and
Osteopontin are mutually exclusive in post natal heart valves and
limbs.
Sox9 loss of function in chondrocyte cultures and heart
valve explants promotes Spp1 and represses cartilage
gene expression
To determine the effects of Sox9 function on Spp1 expression,
primary cultures were derived from post natal mouse rib
chondrocytes or mitral valve explants and treated with adenovirus
to target Sox9 function. Gene knockdown was achieved by
infecting primary cultures isolated from Sox9
fl/fl mice with
adenovirus (AdV) producing Cre recombinase (AdV-Cre), while
infection with AdV containing full length murine Sox9 (AdV-
Sox9), served as an overexpression model [25]. As a control,
cultures were infected with an equal titer of GFP-producing
adenovirus (AdV-GFP) that did not alter Sox9 expression (data not
shown). Compared to endogenous levels (AdV-GFP), Sox9
expression was increased (164-fold632.13, 20-fold68.7) and
decreased (0.59-fold60.07, 0.27-fold60.08) at transcript and
protein levels following AdV-Sox9 and AdV-Cre treatments
respectively in heart valve explants (Figure 4A) and chondrocyte
cultures (Figure 4B). In addition to reducing Sox9, AdV-Cre
significantly increased Spp1 expression in both culture systems and
reduced CLP and Col2a1 expression in chondrocytes (Figure 4B).
CLP and Col2a1 expression levels were not altered in treated heart
valve explants despite our previous studies showing downregula-
tion in valves from embryonic Col2a1cre;Sox9
fl/fl mice. This
discrepancy is likely due to differences in endogenous CLP and
Col2a1 expression levels between the in vivo and in vitro systems.
In contrast to AdV-Cre, AdV-Sox9 treatment in heart valve
explants significantly increased expression of CLP and Col2a1
(Figure 4A), and similarly in chondrocyte cultures, Col2a1 was
increased (Figure 4B). Although trends toward decreased Spp1
expression were observed following AdV-Sox9 infection, signifi-
cant changes were not achieved. This could be due to the low
basal levels of Spp1 in these culture systems prior to adenoviral
infection (Figure 3A, 3C, data not shown). Collectively, these Sox9
targeting experiments show that Sox9 function plays pivotal roles
in regulating cartilage and osteogenic gene expression in cultured
heart valves and chondrocytes.
Spp1 is required for Sox9-mediated calcification of heart
valve and chondrocyte connective tissue
Previous studies in heart valves and limbs have shown that
reduced Sox9 function promotes premature matrix mineralization
[21,25]. To determine if Spp1 is required for this Sox9-mediated
process, heart valve explants and cultured rib chondrocytes
isolated from post natal Sox9
fl/fl mice were subject to infection
with AdV-Cre, and/or an adenovirus containing a short hairpin
(sh) RNA sequence to target Spp1 knockdown (AdV-shSpp1).
Compared to AdV-GFP controls, AdV-Cre and AdV-shSpp1
infection led to successful targeted knockdown of Sox9 and Spp1
respectively (Figure 5A, 5B). In addition, and consistent with our
previous findings [25], AdV-Cre infection increased von Kossa
reactivity in both heart valve explants (Figure 5C, 5E) and cultured
chondrocytes (Figure 5D, 5F). However, the ability of AdV-Cre to
promote von Kossa reactivity was significantly reduced in cultures
pre-treated with AdV-shSpp1 (Figure 5C-5F). This suggests that
Spp1 function is important for Sox9-mediated calcification in
heart valves and chondrocytes.
Discussion
The replacement of cartilage by mineralized tissue is imperative
for development of long bones, ribs and vertebrae [1]. However, it
is equally important that endochondral ossification does not occur
in tissues that must remain cartilaginous, including hyaline
cartilage and heart valves. Aberrations in this process can lead
to ectopic matrix mineralization associated with heterotopic
ossification of the skeletal system and calcification of heart valve
tissue. Therefore it is important that a correct balance of cartilage
and bone is established in the developing embryo and maintained
in the adult. The transcription factor Sox9 has been shown to play
Transcriptional Regulation of Spp1 by Sox9
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luciferase reporter construct pGL3 containing the Spp1 promoter region (no SRY binding sites) (pGL3-spp1p), the 1599 bp 5’ Spp1 enhancer region
containing SRY#1 (pGL3-spp1En), or both the enhancer and promoter regions (pGL3-spp1), along with 200 ng of empty pcDNA (grey bars) or pcDNA
containing full length murine Sox9 (pcDNA-Sox9, black bars). In addition, cells were co-transfected with 20 ng of pGL4 for normalization. Luciferase
activity of pGL3-spp1 with empty pcDNA was set to 100%. Note repression of pGL3-spp1 activity (63%68% (A) and 60.3%612.6% (B) in the presence
of pcDNA-Sox9. Cells were also co-transfected with pcDNA or pcDNA-Sox9 in the presence of pGL3-spp1 in which the SRY#1 had been mutated from
TACAAAG to TAGCAGG (pGL3-spp1mut). Note that pcDNA-Sox9 could not significantly repress pGL3-spp1mut unlike pGL3-spp1. *Student’s
t2test,0.05 compared to pcDNA. (C) qPCR-derived melting curves to show amplification of endogenous 18 s and Runx2 expression levels in HEK293
and MC-3T3 cells.
doi:10.1371/journal.pone.0026769.g002
Transcriptional Regulation of Spp1 by Sox9
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26769pivotal roles in both these processes. While the positive role of
Sox9 in cartilage formation has been well characterized
[5,6,7,8,9,10], its repressive function in osteogenic processes is
less well understood. This study used a genome-wide approach
along with supporting molecular assays and revealed a novel
mechanism in which Sox9 interacts and negatively regulates the
osteoblast-associated glycoprotein, Spp1. Our findings provide
mechanistic insights into the pathological processes of matrix
mineralization associated with human disease.
Calcific disease of the heart valves and vasculature has recently
been described as an active, osteogenic-like process [26]. Despite
our data suggesting that reduced Sox9 function promotes matrix
mineralization via relieved repression of Spp1, Osteopontin and
Sox9 are both highly expressed in human valves excised from
patients with end-stage calcific aortic valve disease
[25,33,34,35,36,37,38]. However, as Osteopontin can be secreted
by both osteoblasts and osteoclasts, it is not clear if high levels in
calcified valves are associated with high affinity for hydroxyapatite
to promote calcification [39,40], or degradation of the mineralized
matrix [41,42,43]. As our data suggests that Spp1 function is
required for matrix mineralization induced by Sox9 knockdown, it
is suggested that high levels promote calcific processes in this
system and reflect the osteogenic phenotype of pathological lesions
[26]. However, while the sufficiency of Spp1 to promote matrix
mineralization in osteoblastic primary cells has previously been
reported [28], further work is required to examine similar
mechanisms in heart valves. In contrast to Osteopontin, it is not
so clear why Sox9 is overexpressed in late stages of calcific aortic
valve disease. As our previous work has shown that reduced Sox9
function promotes calcification [25], it is speculated that increased
Sox9 is a compensatory response to attenuate disease progression.
Based upon findings in this study and others, this is likely at the
level of repressing osteogenic signaling, and/or ‘re-activating’
developmental pathways to promote valve cell proliferation and
differentiation processes, as previously observed in diseased valves
[21,44].
The observed repression of Spp1 by Sox9 complements previous
studies [16,20] and provides an additional mechanism to explain
the calcification phenotypes observed in Sox9 mutant mice [13,25].
However, further work is required to fully understand how Sox9
differentially regulates bone and cartilage target genes in the same
system. One consideration is through the recruitment of
transcriptional co-repressors and co-activators respectively. In
cartilage, PGC-1a and CREB-binding protein associated with
p300 form transcriptional complexes with Sox9 on the enhancer
regions of chondrogenic genes to promote expression [45,46].
However, it is not yet clear if these ‘activating’ complexes are
absent on osteogenic target genes, or replaced by repressive
machinery. In addition to considering loss of co-activators and
recruitment of repressors, studies have also shown that Sox9 can
evoke inhibitory responses on biological process through post-
transcriptional modification. This includes negative regulation by
Figure 3. Temporal and spatial expression of Sox9 and Osteopontin in post natal heart valves and limbs. (A, C) qPCR analysis shows
comparatively higher levels of Sox9 compared to Spp1 at all time points in post natal heart valves and limbs. For both genes, expression is higher
during embryonic development compared to post natal and adult stages. (B, D) Immunohistochemistry reveals mutually exclusive expression
patterns of Sox9 and Osteopontin in post natal tissues. In the heart (B), Sox9 is most highly detectable in heart valve structures (tricuspid valve
shown) (arrow), while Osteopontin expression is observed in the subepicardial region and extracellular matrix within the myocardium (arrowheads).
In the limb (D), the domain of Sox9 expression in developing chondrocytes (arrow) is distinct from that of Osteopontin in adjacent hypertrophic
chondrocytes (arrowhead).
doi:10.1371/journal.pone.0026769.g003
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binding with other signaling proteins for SRY sites [49]. Based
upon the reported complexity of Sox9 regulation, it is likely that
defining molecular codes that determine Sox9 as an activator or
repressor in connective tissue system will not be clear-cut.
However, understanding more thoroughly how Sox9 mediates
antagonism between cartilage and bone signaling pathways would
have significant impact in understanding developmental and
disease processes.
In summary, this current study highlights a novel mechanism by
which Sox9 acts as a transcriptional repressor of Spp1 to prevent
matrix mineralization in heart valves and chondrocytes, in vitro.
Despite these two connective tissue systems being functionally
diverse, there is ever-increasing evidence to show that normal
heart valve ECM shares molecular characteristics and signaling
pathways with chondrogenesis [21,23,25]. Similarly, pathological
calcification of heart valve ECM has recently been referred to as a
bone-like process, although parallel ‘endochondral ossification’
events in valve interstitial cells have not been yet reported in
human patients or mouse models of valve calcification. Nonethe-
less, our findings provide further support to show overlapping
regulatory pathways between these two connective tissue systems
and identify a previously unappreciated mechanism to prevent
ossification in tissues that must remain cartilaginous for life-long
function.
Methods
Chromatin Immunoprecipitation
ChIP-on-chip array. Sox9 chromatin immunoprecipitation
(ChIP) was performed from post natal wild type mouse limb
chromatin according to manufacturer’s instructions (EZ-ChIP,
Millipore) adapted for use with primary tissue lysates as follows.
One neonate mouse forelimb per immunoprecipitation (IP) was
diced and incubated in hypotonic lysis buffer for 30 minutes on ice
and then vortexed for 10 s. Nuclear-enriched fraction was pelleted
by centrifugation and resuspended in PBS containing 0.5%
formaldehyde (Sigma) for 10 minutes. Chromatin shearing was
achieved with 5, 10-second pulses, with a 10 second minimum
refractory period using a benchtop sonicator (Misonix). IPs were
performed using a total of 5mg of pooled polyclonal rabbit Sox9
antibodies (4 ug SC-17341 (Santa Cruz) and 1mg anti-Sox9
antibody (a kind gift from Dr. Michael Wegner), with 5mgo f
normal rabbit IgG used in parallel control experiments. Each
ChIP was validated by polymerase chain reaction (PCR) to
confirm enrichment of a known Sox9-bound promoter region in
the CLP promoter [8]. Purified DNA from Sox9, and IgG control
ChIP experiments was hybridized to a GeneChipMouse Promoter
1.0R Array (Affymetrix). Data analysis was performed with Tiling
Analysis Software and Integrated Genome Browser (Affymetrix).
Enrichment of target genes was determined by setting a graph
threshold for signal intensity (value$30) and minimum run (100
base pairs) in the Integrated Genome Browser (Affymetrix) based
on a known Sox9 binding site in the CLP promoter.
ChIP-on-chip validation. Sox9 binding to the Spp1 5’ region
observed in the ChIP-on-chip analysis was validated by
quantitative real-time PCR in three independent experiments
with post natal mouse limb lysates. Primers were designed to
amplify 100–200 bp genomic DNA sequences surrounding the
known SRY binding site within the promoter region of CLP: 5’-
GAAAGAGGTAGCTTTTTAAT, 3’-AGCACCACCCTATTGTG
GCT [8], in addition to SRY#1, SRY#2a n dS R Y #3b i n d i n gs i t e so n
Spp1 as detected by the GeneChipMouse Promoter1.0R Array:
SRY#1: 5’-CAATCTATCTCCATTGTCTGTC,3’-CTTTCTCTG
AGATGCCTTCC;
SRY#2: 5’-AGCAGGGTTTGGCAAGTAGCACT 3’-TCC
CGAAATGGAGAACACAGGCT; SRY#3: 5’-TGTATCCAT
GTGGCCTTTATC, 3’-GAGTAGATCACCCTCACAGAGAC.
Real-time PCR was performed using a StepOnePlus Real Time
PCR system (Applied Biosystems) with PefeCTA SYBR Green Fast
Mix(Quanta) according tothe manufacturer’s instructions.Real-time
PCR data for ChIP enrichment is reported as fold increase over IgG,
with significance calculated from fold changes using Student’s t2test.
p,0.05 was considered significant (n=3).
Luciferase Assays
ThepGL3-spp1pconstructwasobtainedfromDr.PaulShoreand
contains a published 829 bp Spp1 promoter sequence [30]. To
generate pGL3-spp1En, a 1599 bp 5’ region of Spp1 (Accession
number AY220127) containing SRY#1 was amplified from
genomic mouse tail DNA by PCR using the following primers
5’TAGGTACCCATTAAGCATTTAACT-TTTCCAGTGATG,
and 3’TGAGCTCCTTCAGCAGAGGCAAGGAG, and ligated
Figure 4. Effects on bone and cartilage gene expression in
heart valve and chondrocyte cultures following Sox9 manip-
ulation. Mitral valve explants (A) and chondrocyte cultures from post
natal Sox9
fl/fl mice (B) were infected for 4 hours with 2.5610
10 PFU/
10 cm
2 adenovirus targeting GFP (AdV-GFP), Cre (Adv-Cre) (grey bars),
or full length murine Sox9 (AdV-Sox9) (black bars) to target knockdown
or overexpression respectively. After 72 hours of initial infection, RNA
was isolated and qPCR performed to examine changes in expression of
Sox9, Spp1 and cartilage genes CLP and Col2a1 compared to AdV-GFP
controls. Note logarithmic scale. *Student’s t2test,0.05 compared to
AdV-GFP. (B inset) Western blot analysis to show Sox9 expression levels
in AdV-Cre, AdV-GFP and AdV-Sox9 treated chondrocytes. a-tubulin
expression is included as a loading control.
doi:10.1371/journal.pone.0026769.g004
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was produced by ligating the 1599 bp spp1 enhancer region into the
pGL3-spp1p plasmid using Kpn1 and Sac1 sites, 5’ of the spp1 promoter
sequence. Site-directed mutagenesis was used to target mutation of the
SRY#1 consensus sequence using the following internal mutagenesis
primers: 5’TGTCTATGGCATTTAAGCAGGGGATAAAA-GAAT
TT and 3’AAATTCTTTTA-TCCCCTGCTTAAATGCCATAGA
CA. This mutated fragment was similarly ligated 5’ of the spp1 promoter
sequence in pGL3-spp1p, to generate pGL3-spp1mut.
Luciferase assays were performed in HEK 293 and MC-3T3
cells (ATCC) plated at 2610
5 or 2610
4 per well of a 24-well plate
respectively, 16–20 hours prior to transfection with Lipofectamine
reagent (Invitrogen) according to manufacturer’s instructions.
200 ng of pGL3-spp1, pGL3-spp1mut or pGL3 (200 ng/well), and
pcDNA or pcDNA-Sox9 (200 ng/well), were co-transfected into
each well, along with 20 ng of pGL4 (Renilla luciferase, Promega).
All transfections were performed in 0.5 mL OptiMem for 4 hours
before the addition of 0.5 mL DMEM (Sigma) supplemented with
4 mM L-Glutamine and 10% FBS. Cell lysates were collected
24 hours following transfection according to the manufacturer’s
instructions for dual luciferase assays (Promega). Data is
represented as an average percent of luciferase activity of the
pGL3-spp1 co-transfected with pcDNA (set at 100%) and
normalized to pGL4 Renilla signal (n=3–8).
Figure 5. The requirement of Spp1 for Sox9-mediated matrix mineralization. Primary heart valve explants (A, C, E) and chondrocyte
cultures (B, D, F) were infected with AdV-GFP, AdV-Cre or AdV-shSpp1 for 4 hours. In addition after 24 hours of infection, AdV-shSpp1 treated cultures
were also treated with AdV-Cre. After 72 hours, RNA was isolated and qPCR performed to show expected Sox9 and Spp1 gene knockdown following
AdV-Cre and AdV-shSpp1 infection respectively, compared to AdV-GFP. Alternatively, treated cultures were fixed and stained with von Kossa and
alcian blue to detect mineralization and proteoglycan secretion respectively. (E, F) Quantitation of von Kossa reactivity normalized to area (alcian blue
positive) in treated cultures compared to AdV-GFP controls. *Student’s t2test,0.05 compared to AdV-GFP.
doi:10.1371/journal.pone.0026769.g005
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Post natal mouse limbs and heart valves from E12.5, E18.5 and
3 month old adult mice were processed unfixed, through 10, 20
and 30% sucrose solutions before embedding in OCT freezing
compound (Tissue-Tek) and sectioned at 10mm-thick. Frozen
sections were post-fixed in 100% acetone for 10 minutes at 220uC
and rinsed in 1xPBS prior to immunofluorescent staining as
described [25] using antibodies against Sox9, a kind gift from Dr.
Michael Wegner at 1:1000 dilution, and Osteopontin (Santa Cruz
sc-10593) at 1:100 dilution. Following primary antibody incuba-
tion, sections were washed in 1xPBS and incubated with respective
anti-rabbit and anti-goat Alexa 488 or 568 secondary antibodies at
1:400/1xPBS dilution for 1 hour at room temperature, washed,
and incubated with DAPI (blue) for identification of nuclei before
mounting in Vectashield (Vector Laboratories).
Primary Culture Systems
Heart valve explants. Mitral valve explants were isolated
from post natal Sox9
fl/fl mice and cultured as previously described
[25]. Valve explant cultures were infected immediately after
dissection with 1610
10 PFU/filter AdV-shSpp1 produced by
Vector Biolabs using a commercially available Spp1 targeting
shRNA (174_0576-H-5, Open Biosystems) or control AdV-GFP
[25]. Adenoviral infections were conducted in serum free medium
for 4 hours before incubation in regular culture medium for 20
additional hours. 24 hours following the initial infections (AdV-
shSpp1 or AdV-GFP), valve explants were treated with AdV-Cre
(Vector Labs) or control Ad-GFP at 1610
10 PFU in serum free
medium for 4 hours before incubation in regular culture medium
for an additional 68 hours. This provided valve explants with loss
of Spp1 expression prior to Sox9 knockdown, or infection with
controls including Spp1 knockdown only, Sox9 knockdown only, or
AdV-GFP. After 72 hours of infection, treated explants were
removed for histological analysis [25] or RNA was extracted using
standard Trizol protocols (Invitrogen) and cDNA was synthesized
from 200 ng RNA using the qScriptcDNA Synthesis Kit (Quanta)
for real-time PCR analysis.
Chondrocyte cultures. Primary chondrocytes were
prepared from rib cartilage of postnatal day 1–3 Sox9
fl/fl mice,
according to an established protocol designed to maintain
chondrocyte differentiation in monolayer culture [50]. Following
18 hours of culture, primary chondrocytes were infected with
AdV-GFP or AdV-shSpp1 at 2.5610
10 PFU/10 cm
2 in serum free
medium for 4 hours before incubation in regular culture medium
(DMEM supplemented with 2 mM L-Glutamine and 10% FBS)
for an additional 20 hours. 24 hours following the initial infections
(AdV-shSpp1 or AdV-GFP), chondrocytes were treated with AdV-
Cre (Vector Labs) or control AdV-GFP at 2.5610
10 PFU/10 cm
2
in serum free medium for 4 hours and then incubated in regular
culture medium for an additional 68 hours. After 72 hours of
infection, treated chondrocytes were fixed in 4%
paraformaldehyde for histological analysis or RNA was extracted
using standard Trizol protocols (Invitrogen) and cDNA was
synthesized from 200 ng RNA using the qScriptcDNA Synthesis
Kit (Quanta) for real-time PCR analysis. All animal procedures
were approved by The University of Miami Institutional Animal
Care and Use Committee (protocol # 09-171) and performed in
accordance with institutional guidelines.
Primary Cultures: Polymerase Chain Reaction
Quantitative real-time PCR was performed using a Step One
Plus Real Time PCR system (Applied Biosystems) with the
following TaqMan assays (Applied Biosystems): Human 18 s and
mouse Sox9, Spp1, CLP and Col2a1. Reactions were performed
using 10ml PerfeCTAFastMix (Quanta), 1mlTaqMan assay, 1ml
cDNA, and 8mldeionized water per reaction. Real-time PCR for
ChIP validation was performed using 10ml PerfeCTA SYBR
Green FastMix (Quanta) with 0.5ml of each primer (at 20 pmol/
ml), 1ml cDNA and 8ml deionized water per 20ml reaction. All
reactions were performed with a 20 second activation step at 95uC
followed by 40 cycles with 1 second denaturation at 95uC and a 20
second annealing/polymerization step at 60uC.
Western Blotting
Protein lysates from treated chondrocyte cultures (1 well of a 6-
well plate) were collected and lysed in 16 buffer (20 mM Tris
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton
X2100, 2.5 mM Sodium pyrophosphate, 1 mM b-glycerophos-
phate, 1 mM Na3VO4, supplemented with complete EDTA free
protease inhibitor cocktail). 30mg of total protein was run on a
12% SDS PAGE gel and transferred to nitrocellulose membranes.
Membranes were blocked in 5% fat free dried milk for 1 hr and
probed with antibodies against Sox9 (1:1000, 1 hr, Santa Cruz)
and a-tubulin (1:10,000, 1 hr, Chemicon/Millipore), followed by
incubation with anti-rabbit-horseradish peroxidase (HRP)-conju-
gated secondary antibody (1:10,000, 1 hr, Cell Signaling).
Membranes were then washed three times in 16 TBST for 10
minutes. Western blots were developed using Super Signal West
Femto Substrate (Pierce) and BioMax MR film (Eastman Kodak).
Primary Cultures: Histology
Following culture and viral infection as described (Section 4.4),
one mouse valve explant per filter was mounted and von Kossa
staining was performed as described previously [25]. Chondrocyte
cultures were stained following a similar protocol; cells were rinsed
in PBS, fixed in 4% paraformaldehyde, washed 3 times in
deionized water, and incubated in 5% silver nitrate solution for
1 hour under direct light (Schott Modulamp) in a reflective
chamber. Chondrocytes were then washed in water, differentiated
in 5% sodium thiosulfatepentahydrate for five minutes, and rinsed
and counterstained for 20 minutes in 1% Alcian blue in 20%
acetic acid. Quantification of von Kossa reactive area was
performed using Image Pro Plus software and calculated as a
percentage of von Kossa positive area (black) over total area
indicated by alcian blue staining.
Supporting Information
Table S1 Data analysis of ChIP-on-chip using Tiling
Analysis Software and Integrated Genome Browser (Affy-
metrix). Enrichment of indicated target genes was determined by
setting a graph threshold for signal intensity (value$30) and minimum
run (100 base pairs) in the Integrated Genome Browser (Affymetrix)
b a s e do nak n o w nS o x 9b i n d i n gs i t ei nt h eCLP promoter.
(XLSX)
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